The market expects Organon (OGN) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is ...

What Happened? A number of stocks jumped in the afternoon session after investor sentiment improved on renewed optimism that ...

BofA lowered the firm’s price target on Organon (OGN) to $11 from $15 and keeps an Underperform rating on the shares. The firm, in its preview ...

Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.

Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Organon (OGN – Research Report) today and set a price target of ...

Organon, a women’s health-focused pharma company based in Jersey City, expects to eliminate 93 jobs as part of an effort to optimize internal operations. In a filing with the state Department of Labor ...

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

Organon (OGN) closed at $11.30 in the latest trading session, marking a +1.07% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.79% for the day. Elsewhere ...

Access our full analysis report here, it’s free. Branded Pharmaceuticals company Organon (NYSE:OGN) jumped 7%. Is now the time to buy Organon? Access our full analysis report here, it’s free.